About the Company
We do not have any company description for CEL SCI CORP at the moment.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on CEL SCI CORP
Cel-Sci's Successful Safety Review Not Yet Factored Into Valuation
CEL-SCI Corp. (AMEX: NYSE:CVM) released news last week that pretty much went unnoticed by investors during a very rough negative trending market, this judging by the non-reaction of the company's ...
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...
CEL-SCI Corp letter to shareholders details positive results from Phase ...
CEL-SCI Corp CEO Geert Kersten joined Steve Darling from Proactive to share news the company has detailed, in a letter to shareholders, the good results from its Phase 3 study of our investigational ...
CVM | CEL-SCI Corp. Annual Cash Flow Statement | MarketWatch
CEL-SCI Corp. Annual cash flow by MarketWatch. View CVM net cash flow, operating cash flow, operating expenses and cash dividends.
2024-02-09 | NYSEAM:CVM | Press Release | CEL-SCI Corp
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 3,875,000 shares of its common stock at an ...
LSRM - CEL-SCI Corp Financials & Balance Sheets - XMUN - Morningstar
Review quarterly and annual revenue, net income, and cash flow for CEL-SCI Corp (LSRM:XMUN) stock through the last fiscal year.
Cel-Sci Corp (CVM-A) Quote - Press Release - The Globe and Mail
CEL-SCI Corporation (NYSE American: CVM) today announced the availability to the public of an oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall ...
LSRM - CEL-SCI Corp Executives | Morningstar
Learn about the executive team and board of directors at CEL-SCI Corp (LSRM:XMUN) and review their bios and compensation over the latest fiscal years.
CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Nasdaq
CEL-SCI Corporation ( CVM ) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a ...
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial ...
VIENNA, Va.-- (BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2022, as well as key clinical and corporate developments.
Cel-Sci Corp (CVM-A) Quote - Press Release
CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) annual Congress on September 10, 2022 in Paris ...
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2020 and provided an update on clinical developments: On May ...
Similar Companies
Loading the latest forecasts...